Researchers developed 26 novel cell-penetrating peptides for blood cancers, with two top candidates significantly enhancing PROTAC delivery into leukemia cells and improving Bcr-Abl protein degradation.
26 peptides designedwith two top candidates significantly boosting PROTAC delivery into leukemia cells and enhancing cancer protein destruction
What the researchers found
Two novel penetrating peptides (C9C-f(3Bta) and Cyclo-C9C-R) significantly enhanced intracellular PROTAC content in K562 leukemia cells, facilitated Bcr-Abl protein degradation, reduced STAT5 phosphorylation, and promoted apoptosis.
Why it matters
PROTACs represent the next frontier of cancer therapy, but their poor cell entry is a major limitation. Cancer-targeting peptides that solve this delivery problem could unlock PROTAC therapy for blood cancers and potentially many other cancer types.
The numbers in context
Novel penetrating peptides demonstrated enhanced PROTAC delivery specifically into leukemia and lymphoma cells.
How the study worked
Designed and screened 26 novel targeted penetrating peptides for leukemia/lymphoma cells. Assessed membrane permeability, cancer targeting, and stability. Combined top candidates with IMA-PROTAC and evaluated anti-proliferative activity, Bcr-Abl degradation, STAT5 signaling, apoptosis, and cell cycle effects. Quantified intracellular PROTAC by HPLC-MRM-MS.
Who was studied
Human leukemia and lymphoma cell lines
What this study cannot tell us
In vitro cell culture study using cancer cell lines. In vivo efficacy, pharmacokinetics, and selectivity need demonstration. Peptide stability in blood and tissue penetration in living systems are unknown. The peptide-PROTAC combination approach adds manufacturing complexity.
How to read the evidence
Preliminary evidence: proof-of-concept in vitro study published in the European Journal of Medicinal Chemistry. Promising but requires in vivo validation.
When this study was published
Published in 2024. Addresses a critical limitation of PROTAC cancer drugs.
The bigger picture
PROTACs are widely considered the next generation of targeted cancer therapy, but delivery remains their Achilles heel. This study demonstrates that cancer-specific cell-penetrating peptides can bridge the gap, turning PROTACs from laboratory tools into potentially viable cancer drugs. The approach could be generalizable to PROTAC delivery across many cancer types.
Questions still open
- Do these penetrating peptides maintain selectivity for cancer cells over normal cells in vivo?
- Can this approach be applied to PROTACs targeting other cancer-driving proteins beyond Bcr-Abl?
- What are the pharmacokinetic properties and in vivo stability of these peptide-PROTAC combinations?
Common questions
What are PROTACs and why do they need peptide help?
Could this help treat leukemia?
Read the original research
Discovery of novel penetrating peptides able to target human leukemia and lymphoma for enhanced PROTAC delivery.
European journal of medicinal chemistry, 277, 116734
Citation
Zhang, Qingqing; Liu, Yuying; Zhang, Jie; Li, Yanchen; Wang, Jin; Liu, Nanxin; Zhang, Jie; Pan, Xiaoyan. (2024). Discovery of novel penetrating peptides able to target human leukemia and lymphoma for enhanced PROTAC delivery.. European journal of medicinal chemistry, 277, 116734. https://doi.org/10.1016/j.ejmech.2024.116734